Trial · NCT07520760
A Multicenter, Single-Arm, Phase II Exploratory Study of Eribulin in Combination With Anlotinib for HER2-Negative Recurrent/Metastatic Breast Cancer Previously Treated With Antibody-Drug Conjugates
NCT07520760, Phase 2, Recruiting, Sun Yat-sen University
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. A Multicenter, Single-Arm, Phase II Exploratory Study of Eribulin in Combination With Anlotinib for HER2-Negative Recurrent/Metastatic Breast Cancer Previously Treated With Antibody-Drug Conjugates. Trials, record NCT07520760. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07520760
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Multicenter, Single-Arm, Phase II Exploratory Study of Eribulin in Combination With Anlotinib for HER2-Negative Recurrent/Metastatic Breast Cancer Previously Treated With Antibody-Drug Conjugates
- NCT number
- NCT07520760
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 52 participants, estimated
- Lead sponsor
- Sun Yat-sen University
- Conditions
- HER 2 Negative Breast Cancer
- Interventions
- Eribulin in Combination with Anlotinib
- First posted
- 2026-04-09
- Last updated
- 2026-04-09
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Progression free survival | From date of first dose until the date of first documented disease progression per RECIST v1.1 or death from any cause, whichever occurs first, assessed up to 24 months | Progression free survival (PFS) is defined as the time from the first dose of study treatment to the first documented disease progression per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, or death from any cause, whichever occurs first. For patients who have not experienced disease progression or death at the time of analysis, PFS will be censored at the date of the last adequate tumor assessment. If no post-baseline tumor assessment is available, PFS will be censored at the date of first dose. Disease progression is determined by investigator assessment based on imaging evaluations (e.g., CT, MRI) performed at baseline and at scheduled time points throughout the study. Unit of Measure: Months |
| Secondary | Overall survival | From date of first dose until death from any cause, assessed up to 36 months | Overall survival (OS) is defined as the time from the first dose of study treatment to death from any cause. For patients who are alive at the time of analysis, OS will be censored at the last known date the patient was known to be alive. If no post-baseline follow-up information is available, OS will be censored at the date of first dose. Survival status is collected through scheduled follow-up visits and/or via telephone contact at the end of the study. Unit of Measure: Months |
| Secondary | Safety | From date of informed consent through 30 days after last dose of study treatment | Safety and tolerability will be assessed by evaluating the incidence, severity, and causality of adverse events (AEs) and serious adverse events (SAEs). AEs will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0. Unit of Measure: Number of participants |
| Secondary | Quality of Life (QoL) | From baseline to end of study follow-up, assessed up to 24 months | Quality of life will be assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) and the breast cancer-specific module. Unit of Measure: Score on a scale |
| Other | Prevalence of PIK3CA, ESR1, and GATA3 (PEG) Gene Mutations | Baseline | The presence or absence of mutations in the PIK3CA, ESR1, and GATA3 genes (PEG gene panel) will be assessed using next-generation sequencing (NGS) performed on tumor tissue or circulating tumor DNA (ctDNA) collected at baseline. Unit of Measure: Mutant-type category (Mutant vs. Wild-type) |
| Other | Change in Metabolite Concentrations | Baseline and during study treatment | Blood samples will be collected at baseline and during study treatment. Metabolomic profiling will be performed using liquid chromatography-mass spectrometry (LC-MS) to identify and quantify the concentration of specific metabolites. Unit of Measure: Concentration (μM or relative abundance) |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07520760
GET https://conductscience.org/api/trials/v1/NCT07520760/registered